New Curcumin Extract Found to Counteract Inflammation At the Genetic Level19-Apr-2017
Vancouver, CANADA, April 19, 2017 – New biomedical research discovery released today shows that a trace component of the standard curcumin extract, bisdemethoxycurcumin (BDMC), is proven to be up to 7X more potent on a key anti-inflammatory target than the curcumin extract itself. This discovery allows curcumin pharmacology to be more precisely targeted for therapeutic results.
The research on this patent-pending discovery is the work of The Rhema Group’s Chief Science Officer, Franco Cavaleri, BSc, PhDc. He is the principal research scientist at Biologic Pharmamedical, and also completing a doctoral degree in Experimental Medicine at UBC’s Faculty of Medicine, Center for Brain Health. Cavaleri’s research shows for the first time how the modified curcumin extract targets and neutralizes a key protein central in the regulation of inflammation while significantly enhancing the efficacy of the anti-inflammatory properties of curcumin.
"Inflammation is central to every disease pathology at one level or another. This new pointed pharmacological research on curcumin reveals that although BDMC exists in extremely low concentrations in standardized curcumin extracts - between 0.5% to 1.5% - it can play a key role in therapy if it is raised to 30%. This enhancement fortifies the mechanism by which curcumin can inhibit nuclear, MSK1, a facilitative kinase protein central to the inflammatory process. MSK1, is more recently shown to be dysregulated in diseases like drug resistant cancers and chronic or drug resistant autoimmune disease.” says Cavaleri.
This new understanding reveals how curcumin pharmacology can be designed to be more selective in targeting specific genomic activity. Elevated levels of BDMC to 30% is showing dramatic results.
The Rhema Group, a leading nutraceutical formulator and manufacturer to global markets, has partnered with Biologic Pharmamedical Research, a private biomedical research organization, to bring to market patent-protected formulations with BDMC levels elevated to 30% under the trade name Curcumin BDM30™. Both companies are working together to use Cavaleri’s patent-pending research to develop new evidence-based curcumin-drug and supplement designs for the functional food and nutraceutical industry. This inflection is expected to change how curcumin is prescribed in the future to help improve lives.
Cavaleri will be attending SupplySide West 2016 in Las Vegas on October 6 and 7, and will be giving informal presentations on his patent-pending research on Curcumin BDM30™, and how companies can use this new ingredient in their formulations. He can be contacted via the info below or by visiting The Rhema Group’s booth # K111.
- 30 -
About The Rhema Group:
Rhema formulates, flavours and manufactures for some of the world's top nutraceutical brands. The company has developed a model for Rapid Formulation and Flavouring, that reduces nutraceutical development time from months to weeks, and allows clients to develop and manufacture award winning products. For more information, visit rhemamade.com.
About Biologic Pharmamedical Research:
Biologic Pharmamedical researches and develops nutrient and nutraceutical based technologies or analogues of natural compounds using pharmaceutical or medical research models to help define how they interact and modulate cell signalling and behaviour. The genomic influences and proteomic changes induced by these botanical extracts and their molecular constituents are identified and mapped, and then related to disease pathology. For more information, visit biologic-med.com.
email@example.com | 604.240.3196